The beneficial oncological effects of these antagonists in experimental cancer treatment can be attributed to the suppression of pituitary-hepatic IGF-I axis and the direct inhibition through the binding of GHRH antagonists to pituitary GHRH-R and/or their splice variants present on tumors [36,50,55]. The gene discussed is GHRHR; the disease is cancer.